PCVX

Vaxcyte, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $56.05
52-Week Range: $39.87 – $65.00
Market Cap: $8.40B
P/E (TTM): —
EPS (TTM): -7.62
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.97
PEG Ratio: —
Return on Equity: -36.51%
Return on Assets: -22.61%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 5.72
Debt/Equity: 0.04
Total Debt: $115.44M
Free Cash Flow: $-485.76M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $7.03B

PCVX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$169.45M	$332.34M	$476.64M	$794.31M
Selling, General & Admin	$39.81M	$60.70M	$92.90M	$129.37M
Operating Expenses	$209.26M	$393.04M	$569.55M	$923.67M
Operating Income	-$209.26M	-$393.04M	-$569.55M	-$923.67M
EBITDA	-$214.03M	-$382.87M	-$553.70M	-$898.82M
Pretax Income	-$223.49M	-$402.27M	-$463.93M	-$766.63M
Net Income	-$223.49M	-$402.27M	-$463.93M	-$766.63M
Diluted EPS	-3.44	-4.14	-3.80	-5.63
Diluted Shares	64.88M	97.16M	122.00M	136.09M

PCVX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$834.66M	$397.45M	$387.88M	$173.96M
Current Assets	$942.55M	$1.10B	$1.79B	$1.63B
Total Assets	$1.01B	$1.41B	$3.51B	$3.00B
Current Liabilities	$40.52M	$145.34M	$140.18M	$205.75M
Total Debt	$17.94M	$29.22M	$71.11M	$117.48M
Total Liabilities	$52.56M	$167.45M	$205.50M	$317.21M
Retained Earnings	-$522.13M	-$924.39M	-$1.39B	-$2.15B
Shareholders' Equity	$953.61M	$1.24B	$3.31B	$2.69B
Working Capital	$902.03M	$950.62M	$1.65B	$1.42B

PCVX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$170.60M	-$296.79M	-$452.63M	-$655.58M
Capital Expenditure	-$5.84M	-$67.88M	-$119.16M	-$56.97M
Free Cash Flow	-$176.44M	-$364.67M	-$571.79M	-$712.55M
Depreciation & Amortisation	$9.45M	$10.17M	$15.85M	$24.86M
Stock-Based Compensation	$23.65M	$48.76M	$84.82M	$138.84M
Investing Cash Flow	$74.58M	-$773.31M	-$2.01B	$437.35M
Financing Cash Flow	$861.55M	$639.81M	$2.45B	$2.01M
Net Change in Cash	$765.53M	-$430.29M	-$9.79M	-$216.21M

PCVX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$148.13M	$194.18M	$209.93M	$242.06M	$312.78M	$267.85M
Selling, General & Admin	$32.66M	$32.04M	$32.45M	$32.22M	$33.07M	$34.92M
Operating Expenses	$180.79M	$226.22M	$242.38M	$274.28M	$345.85M	$302.78M
Operating Income	-$180.79M	-$226.22M	-$242.38M	-$274.28M	-$345.85M	-$302.78M
EBITDA	-$175.92M	-$221.23M	-$237.18M	-$264.48M	-$340.00M	-$296.85M
Pretax Income	-$140.72M	-$166.57M	-$212.83M	-$246.51M	-$320.62M	-$284.30M
Net Income	-$140.72M	-$166.57M	-$212.83M	-$246.51M	-$320.62M	-$284.30M
Diluted EPS	-1.04	-1.22	-1.56	—	-2.30	-1.97
Diluted Shares	135.69M	136.03M	136.20M	—	139.51M	144.49M

PCVX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$346.85M	$306.74M	$281.08M	$173.96M	$260.84M	$183.19M
Current Assets	$1.72B	$1.72B	$1.77B	$1.63B	$1.81B	$1.55B
Total Assets	$3.38B	$3.31B	$3.17B	$3.00B	$3.35B	$3.14B
Current Liabilities	$97.00M	$154.49M	$200.05M	$205.75M	$242.08M	$271.28M
Total Debt	$87.21M	$85.84M	$84.44M	$117.48M	$116.30M	$115.44M
Total Liabilities	$178.08M	$234.03M	$278.72M	$317.21M	$352.29M	$380.21M
Retained Earnings	-$1.53B	-$1.70B	-$1.91B	-$2.15B	-$2.48B	-$2.76B
Shareholders' Equity	$3.20B	$3.07B	$2.89B	$2.69B	$3.00B	$2.76B
Working Capital	$1.62B	$1.56B	$1.57B	$1.42B	$1.57B	$1.28B

PCVX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$166.27M	-$121.17M	-$143.31M	-$224.83M	-$280.63M	-$232.47M
Capital Expenditure	-$26.75M	-$9.76M	-$12.05M	-$8.42M	-$14.79M	-$4.57M
Free Cash Flow	-$193.03M	-$130.92M	-$155.35M	-$233.25M	-$295.42M	-$237.04M
Depreciation & Amortisation	$4.87M	$4.99M	$5.20M	$9.80M	$5.85M	$5.93M
Stock-Based Compensation	$30.61M	$36.93M	$35.31M	$36.00M	$37.96M	$41.24M
Investing Cash Flow	$123.32M	$77.74M	$121.17M	$115.13M	-$233.41M	$147.72M
Financing Cash Flow	$759.00K	$2.52M	-$3.67M	$2.41M	$601.58M	$5.70M
Net Change in Cash	-$42.20M	-$40.91M	-$25.81M	-$107.30M	$87.55M	-$79.05M

Market Snapshot

About

Vaxcyte is a clinical-stage biotechnology company developing next-generation vaccines to prevent bacterial infectious diseases. The company focuses on pneumococcal, Group A Strep, and periodontitis prevention using its XpressCF cell-free protein synthesis platform. Lead candidate VAX-24 is a 24-valent pneumococcal conjugate vaccine.